Answers are grounded in this paper and cite their sources.
Palbociclib was not effective at treating nonbreast solid tumors with a CCND1, 2, or 3 amplification in this cohort. These data do not support further investigation of single-agent palbociclib in tumors with CCND1, 2, or 3 amplification.
No takes yet. Share an insight, caveat, or question.
Clark et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: